Zhu Xiangyun, Wu Chunhua, Qiu Shanhu, Yuan Xuelu, Li Ling
Department of Endocrinology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, 210009 China.
Nutr Metab (Lond). 2017 Sep 22;14:60. doi: 10.1186/s12986-017-0217-z. eCollection 2017.
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus (T2DM), the reported results are inconsistent. Thus, we aimed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM. We searched for relevant articles published until June 2017 on PubMed-Medline, Embase, Cochrane Library, and Web of Science. Randomized controlled trials in T2DM patients administered with resveratrol as intervention were included. After study selection, quality assessment and data extraction were performed independently by two authors, and STATA and RevMan software were used for statistical analysis. Nine randomized controlled trials involving 283 participants were included. Meta-analysis showed that resveratrol significantly improved the fasting plasma glucose ( -0.29 mmol/l, 95% CI: -0.51, -0.06, < 0.01) and insulin levels (-0.64 U/mL, 95% CI: -0.95, -0.32, < 0.0001). The drug also reduced homeostasis model assessment of insulin resistance (HOMA-IR) index, systolic blood pressure, and diastolic blood pressure among participants with T2DM. The changes in hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were negligible. Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose. In particular, the latter dose presented more favorable results. This meta-analysis provides evidence that supplementation of resveratrol may benefit management of T2DM.
尽管已知经常食用白藜芦醇可改善2型糖尿病（T2DM）患者的葡萄糖稳态并逆转胰岛素抵抗，但报道的结果并不一致。因此，我们旨在评估白藜芦醇对T2DM患者血糖控制和胰岛素敏感性的影响。我们检索了截至2017年6月在PubMed-Medline、Embase、Cochrane图书馆和科学网发表的相关文章。纳入以白藜芦醇作为干预措施的T2DM患者的随机对照试验。研究选择后，由两位作者独立进行质量评估和数据提取，并使用STATA和RevMan软件进行统计分析。纳入了9项涉及283名参与者的随机对照试验。荟萃分析表明，白藜芦醇显著改善了空腹血糖（-0.29 mmol/l，95%CI：-0.51，-0.06，P<0.01）和胰岛素水平（-0.64 U/mL，95%CI：-0.95，-0.32，P<0.0001）。该药物还降低了T2DM参与者的胰岛素抵抗稳态模型评估（HOMA-IR）指数、收缩压和舒张压。糖化血红蛋白（HbA1c）、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇的变化可忽略不计。比较白藜芦醇补充剂量<100 mg/d与≥100 mg/d的亚组分析显示空腹血糖存在显著差异。特别是，后一种剂量呈现出更有利的结果。这项荟萃分析提供了证据，表明白藜芦醇补充剂可能有益于T2DM的管理。
